Kriya Therapeutics

D轮

Kriya Therapeutics is a next-generation gene therapy company focused on designing and developing transformative gene therapies for highly prevalent serious chronic diseases.In November 2022, Kriya Therapeutics acquired Redpin Therapeutics Inc.In January 2022, Kriya Therapeutics Inc acquired Warden Bio.In July 2023, Kriya Therapeutics Inc announced the addition of over $150 million in capital committed as part of its Series C Financing, bringing the total Series C round to $430 million.In May 2022, Kriya Therapeutics announced a $270 Million Series C financing led by Patient Square Capital, with participation from Bluebird Ventures, CAM Capital, Dexcel Pharma, Foresite Capital, JDRF T1D Fund, Lightswitch Capital, Narya Capital, QVT, Transhuman Capital, and other undisclosed investors.In May 2020, the company raised $80.5 million in a series A financing

https://kriyatherapeutics.com/

470295

基本信息

公司全称

Kriya Therapeutics Inc
类型

基因治疗新药研发商
产业领域

医药研发/制造、化学&生物药
公司人数

15人以下
地址

1100 Island Drive Suite 203 REDWOOD CITY CALIFORNIA 94065; US; Telephone: +18335749289;
联系电话

1-833-574-9289
邮箱

info@kriyatherapeutics.com
成立时间

2019-01-01

投融资

2025-09-10

D轮

PremjiInvest

Patient Square Capital

Narya Capital
2025-08-16

未公开

未透露
2023-07-26

C轮

Patient Square Capital
2022-05-16

C轮

Patient Square Capital

CAM Capital

JDRF T1D Fund

Lightswitch Capital

QVT Financial

Bluebird Ventures

Transhuman Capital

Foresite Capital

Narya Capital

Dexcel Pharma
2021-07-14

B轮

Amplo

Patient Square Capital

CAM Capital

Alumni Ventures

JDRF T1D Fund

QVT Financial

Bluebird Ventures

Woodline Partners

Foresite Capital

Narya Capital

Transhuman Capital

Dexcel Pharma
2020-05-12

A轮

Amplo

Bluebird Ventures

QVT Financial

Transhuman Capital

Dexcel Pharma

Foresite Capital

Narya Capital

Asia Alpha

Paul Manning
2019-12-01

种子轮

Transhuman Capital
加载更多

Kriya Therapeutics

基本信息

投融资

相关投融资企业